Systems and methods for screen electrode securement

Information

  • Patent Grant
  • 8747400
  • Patent Number
    8,747,400
  • Date Filed
    Wednesday, August 13, 2008
    15 years ago
  • Date Issued
    Tuesday, June 10, 2014
    10 years ago
Abstract
Systems and methods for securing a screen-type active electrode to the distal tip of an electrosurgical device used for selectively applying electrical energy to a target location within or on a patient's body. A securing electrode is disposed through the screen electrode and mechanically joined to an insulative support body while also creating an electrical connection and mechanical engagement with the screen electrode. The electrosurgical device and related methods are provided for resecting, cutting, partially ablating, aspirating or otherwise removing tissue from a target site, and ablating the tissue in situ. The present methods and systems are particularly useful for removing tissue within joints, e.g., synovial tissue, meniscus, articular cartilage and the like.
Description
FIELD OF THE INVENTION

The present invention relates generally to the field of electrosurgery, and more particularly to apparatus and methods for applying high frequency voltage to ablate tissue. More particularly, the present invention relates to apparatus and methods for securing a substantially flat screen-type active electrode to the distal tip of the shaft of an electrosurgical instrument.


BACKGROUND OF THE INVENTION

Conventional electrosurgical methods are widely used since they generally achieve hemostasis and reduce patient bleeding associated with tissue cutting operations while improving the surgeon's visibility of the treatment area. Many of the electrosurgical devices used in electrosurgery make use of a screen-type active electrode which is typically cut, or etched, from a sheet of conductive material. These electrosurgical devices and procedures, however, suffer from a number of disadvantages. For example, screen-type active electrodes typically require some method of securement to an insulative body and furthermore to the distal tip of the device itself. Failure to adequately secure the screen electrode to the insulative body may result in improper device function and possible patient harm during the electrosurgical procedure.


Prior attempts to secure the screen active electrode to the insulative body have involved mechanical, thermal, and chemical means or various combinations thereof. Numerous mechanical forms of securement have been utilized, while adhesives have been used as a chemical form of joining, and welding the screen may provide one thermal method of joining. These mechanical joining methods may also include the use of plastic, or non-recoverable, deformations of the materials being used for securement. However, even in combination with other joining methods, the above-listed methods for fixation provide only marginally effective solutions that typically are challenged over extended periods of use.


Accordingly, devices and methods which allow for the securement of flat screen active electrodes to the insulative body of an electrosurgical instrument while maintaining electrical connections through the insulative body are desired. In particular, mechanical methods for providing reasonable and durable securement of an electrically connected screen active electrode to the insulative body at the distal tip of an electrosurgical device while providing enhanced electrosurgical operating parameters are desired.


SUMMARY OF THE INVENTION

The present invention provides systems, apparatus and methods for mechanically securing a screen type active electrode to the insulative body at the distal tip of an electrosurgical device. In particular, methods and apparatus are provided for reliably securing the screen electrode over extended periods of use. Further, the methods and systems of the present invention are particularly useful for providing expanded and enhanced electrosurgical operating parameters.


In one aspect of the invention, the method of securement comprises inserting a securing electrode through a channel or slot in both the screen electrode and insulative body. In a configuration where the screen electrode is supported by the insulative body, the securing electrode functions to mechanically couple the screen electrode to the insulative body, and also functions to electrically couple the screen electrode to a high frequency power supply via electrical connectors. The securing electrode may be characterized by extended leg portions having tabs at one end that engage or interfere with the channel in the insulative body, thereby preventing axial movement of the securing electrode. Thus, the securing electrode provides a mechanical method of joining the screen electrode to the insulative body while also providing an electrical connection to transmit RF energy through the insulative body to the screen electrode.


Another configuration of the electrosurgical device according to the present disclosure comprises an active screen electrode having at least two bilateral channels therethrough. At least two bilateral securing electrodes are provided and are respectively inserted through the channels of the screen electrode. Additionally, the device comprises an insulative support member having at least two bilateral channels correspondingly positioned with regard to the screen electrode channels. The bilateral securing electrodes are inserted through the support member and screen electrode channels and may be oriented symmetrically to thereby allow for creation of a zone for RF ablation between the two securing electrodes. Further, the bilateral screen electrodes each have a leg portion with a tab at one end, wherein the tab slides into a locked position within the support member to secure the screen electrode in place.


In certain configurations, the securing electrodes may be characterized by a saw tooth pattern on a superior surface. Additionally, the securing electrodes may be formed in the shape of a staple or bridge, thereby allowing for the creation of another zone of RF ablation in a space between the staple securing electrode and the screen electrode. The added edges formed on the securing electrode in these configurations may result in increased current density and thus promote the formation of improved zones of RF ablation.


In yet another configuration, the active electrode comprises a conductive screen having a plurality of holes and is positioned over the insulative body at the distal tip of an electrosurgical device in relation to the distal opening of an aspiration lumen. In the representative embodiment, the screen electrode is supported by the insulating support member such that the one of the plurality of holes on the screen is aligned with the aspiration lumen opening, thereby allowing for the aspiration of unwanted tissue and electrosurgery byproducts from the target site. Additionally, the screen and the distal opening of the aspiration lumen may be positioned on a lateral side of the instrument (i.e., facing 90 degrees from the instrument axis).


In open procedures, the system may further include a fluid delivery element for delivering electrically conducting fluid to the active electrode(s) and the target site. The fluid delivery element may be located on the instrument, e.g., a fluid lumen or tube, or it may be part of a separate instrument. Alternatively, an electrically conducting gel or spray, such as a saline electrolyte or other conductive gel, may be applied to the tissue. In addition, in arthroscopic procedures, the target site will typically already be immersed in a conductive irrigant, i.e., saline. In these embodiments, the apparatus may not have a fluid delivery element. In both embodiments, the electrically conducting fluid will preferably provide a current flow path between the active electrode terminal(s) and the return electrode(s). In an exemplary embodiment, a return electrode is located on the instrument and spaced a sufficient distance from the active electrode terminal(s) to substantially avoid or minimize current shorting therebetween and to isolate the return electrode from tissue at the target site.


In another aspect of the invention, a method comprises positioning one or more active electrode(s) (which may include an active screen electrode and securing electrode) at the target site within a patient's body and applying a suction force to a tissue structure to draw the tissue structure to the active electrode(s). High frequency voltage is then applied between the active electrode(s) and one or more return electrode(s) to ablate the tissue structure. Typically, the tissue structure comprises a flexible or elastic connective tissue, such as synovial tissue. This type of tissue is typically difficult to remove with conventional mechanical and electrosurgery techniques because the tissue moves away from the instrument and/or becomes clogged in the rotating cutting tip of the mechanical shaver or microdebrider. The present invention, by contrast, draws the elastic tissue towards the active electrodes, and then ablates this tissue with the mechanisms described above.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a perspective view of an electrosurgical system incorporating a power supply and an electrosurgical probe;



FIG. 2 is a perspective view of another electrosurgical system incorporating a power supply, an electrosurgical probe and a supply of electrically conductive fluid for delivering the fluid to the target site;



FIG. 3 is a side view of an electrosurgical probe for ablating and removing tissue;



FIG. 4 is a cross-sectional view of the electrosurgical probe of FIG. 3;



FIG. 5 illustrates a detailed view illustrating ablation of tissue;



FIG. 6 is an enlarged detailed view of the distal end portion of an embodiment of the probe of FIG. 3;



FIGS. 7A and 7B are detailed view of the securing electrode and screen electrode utilized in the electrosurgical probe of FIG. 6;



FIG. 8 is an exploded view of the distal end portion of the probe of FIG. 6;



FIG. 9 is a perspective view of the distal end portion of the probe of FIG. 6; and



FIG. 10 is a perspective view of the securing electrodes and screen electrode.





DETAILED DESCRIPTION OF THE INVENTION

The present invention provides systems and methods for selectively applying electrical energy to a target location within or on a patient's body. The present invention is particularly useful in procedures where the tissue site is flooded or submerged with an electrically conducting fluid, such as arthroscopic surgery of the knee, shoulder, ankle, hip, elbow, hand or foot. In other procedures, the present invention may be useful for collagen shrinkage, ablation and/or hemostasis in procedures for treating target tissue alone or in combination with the volumetric removal of tissue. More specifically, the embodiments described herein provide for electrosurgical devices characterized by a substantially flat screen active electrode disposed at the distal tip of the device. Additionally, the present embodiments include apparatus and methods for the mechanical securement of the screen electrode to the insulative body located at the distal tip of the device. Such methods of mechanical securement of the screen electrode may extend the operating period of the electrosurgical device by providing a more secure method of attachment.


Before the present invention is described in detail, it is to be understood that this invention is not limited to particular variations set forth herein as various changes or modifications may be made to the invention described and equivalents may be substituted without departing from the spirit and scope of the invention. As will be apparent to those of skill in the art upon reading this disclosure, each of the individual embodiments described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process act(s) or step(s) to the objective(s), spirit or scope of the present invention. All such modifications are intended to be within the scope of the claims made herein.


Methods recited herein may be carried out in any order of the recited events which is logically possible, as well as the recited order of events. Furthermore, where a range of values is provided, it is understood that every intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention. Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein.


All existing subject matter mentioned herein (e.g., publications, patents, patent applications and hardware) is incorporated by reference herein in its entirety except insofar as the subject matter may conflict with that of the present invention (in which case what is present herein shall prevail). The referenced items are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such material by virtue of prior invention.


Reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said” and “the” include plural referents unless the context clearly dictates otherwise. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation. Last, it is to be appreciated that unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.


The electrosurgical device of the present embodiments may have a variety of configurations as described above. However, at least one variation of the embodiments described herein employs a treatment device using Coblation® technology.


As stated above, the assignee of the present invention developed Coblation® technology. Coblation® technology involves the application of a high frequency voltage difference between one or more active electrode(s) and one or more return electrode(s) to develop high electric field intensities in the vicinity of the target tissue. The high electric field intensities may be generated by applying a high frequency voltage that is sufficient to vaporize an electrically conductive fluid over at least a portion of the active electrode(s) in the region between the tip of the active electrode(s) and the target tissue. The electrically conductive fluid may be a liquid or gas, such as isotonic saline, blood, extracelluar or intracellular fluid, delivered to, or already present at, the target site, or a viscous fluid, such as a gel, applied to the target site.


When the conductive fluid is heated enough such that atoms vaporize off the surface faster than they recondense, a gas is formed. When the gas is sufficiently heated such that the atoms collide with each other causing a release of electrons in the process, an ionized gas or plasma is formed (the so-called “fourth state of matter”). Generally speaking, plasmas may be formed by heating a gas and ionizing the gas by driving an electric current through it, or by shining radio waves into the gas. These methods of plasma formation give energy to free electrons in the plasma directly, and then electron-atom collisions liberate more electrons, and the process cascades until the desired degree of ionization is achieved. A more complete description of plasma can be found in Plasma Physics, by R. J. Goldston and P. H. Rutherford of the Plasma Physics Laboratory of Princeton University (1995), the complete disclosure of which is incorporated herein by reference.


As the density of the plasma or vapor layer becomes sufficiently low (i.e., less than approximately 1020 atoms/cm3 for aqueous solutions), the electron mean free path increases to enable subsequently injected electrons to cause impact ionization within the vapor layer. Once the ionic particles in the plasma layer have sufficient energy, they accelerate towards the target tissue. Energy evolved by the energetic electrons (e.g., 3.5 eV to 5 eV) can subsequently bombard a molecule and break its bonds, dissociating a molecule into free radicals, which then combine into final gaseous or liquid species. Often, the electrons carry the electrical current or absorb the radio waves and, therefore, are hotter than the ions. Thus, the electrons, which are carried away from the tissue towards the return electrode, carry most of the plasma's heat with them, allowing the ions to break apart the tissue molecules in a substantially non-thermal manner.


By means of this molecular dissociation (rather than thermal evaporation or carbonization), the target tissue structure is volumetrically removed through molecular disintegration of larger organic molecules into smaller molecules and/or atoms, such as hydrogen, oxygen, oxides of carbon, hydrocarbons and nitrogen compounds. This molecular disintegration completely removes the tissue structure, as opposed to dehydrating the tissue material by the removal of liquid within the cells of the tissue and extracellular fluids, as is typically the case with electrosurgical desiccation and vaporization. A more detailed description of these phenomena can be found in commonly assigned U.S. Pat. No. 5,697,882 the complete disclosure of which is incorporated herein by reference.


In some applications of the Coblation® technology, high frequency (RF) electrical energy is applied in an electrically conducting media environment to shrink or remove (i.e., resect, cut, or ablate) a tissue structure and to seal transected vessels within the region of the target tissue. Coblation® technology is also useful for sealing larger arterial vessels, e.g., on the order of about 1 mm in diameter. In such applications, a high frequency power supply is provided having an ablation mode, wherein a first voltage is applied to an active electrode sufficient to effect molecular dissociation or disintegration of the tissue, and a coagulation mode, wherein a second, lower voltage is applied to an active electrode (either the same or a different electrode) sufficient to heat, shrink, and/or achieve hemostasis of severed vessels within the tissue.


The amount of energy produced by the Coblation® device may be varied by adjusting a variety of factors, such as: the number of active electrodes; electrode size and spacing; electrode surface area; asperities and sharp edges on the electrode surfaces; electrode materials; applied voltage and power; current limiting means, such as inductors; electrical conductivity of the fluid in contact with the electrodes; density of the fluid; and other factors. Accordingly, these factors can be manipulated to control the energy level of the excited electrons. Since different tissue structures have different molecular bonds, the Coblation® device may be configured to produce energy sufficient to break the molecular bonds of certain tissue but insufficient to break the molecular bonds of other tissue. For example, fatty tissue (e.g., adipose) has double bonds that require an energy level substantially higher than 4 eV to 5 eV (typically on the order of about 8 eV) to break. Accordingly, the Coblation® technology generally does not ablate or remove such fatty tissue; however, it may be used to effectively ablate cells to release the inner fat content in a liquid form. Of course, factors may be changed such that these double bonds can also be broken in a similar fashion as the single bonds (e.g., increasing voltage or changing the electrode configuration to increase the current density at the electrode tips). A more complete description of these phenomena can be found in commonly assigned U.S. Pat. Nos. 6,355,032, 6,149,120 and 6,296,136, the complete disclosures of which are incorporated herein by reference.


The active electrode(s) of a Coblation® device may be supported within or by an inorganic insulating support member positioned near the distal end of the instrument shaft. The return electrode may be located on the instrument shaft, on another instrument or on the external surface of the patient (i.e., a dispersive pad). The proximal end of the instrument(s) will include the appropriate electrical connections for coupling the return electrode(s) and the active electrode(s) to a high frequency power supply, such as an electrosurgical generator.


Further discussion of applications and devices using Coblation® technology may be found as follows. Issued U.S. Pat. Nos. 6,296,638; and 7,241,293 both of which are incorporated by reference. Pending U.S. application Ser. No. 11/612,995 filed Dec. 19, 2006, which is incorporated by reference.


In one example of a Coblation® device for use with the presently-described embodiments, the return electrode of the device is typically spaced proximally from the active electrode(s) a suitable distance to avoid electrical shorting between the active and return electrodes in the presence of electrically conductive fluid. In many cases, the distal edge of the exposed surface of the return electrode is spaced about 0.5 mm to 25 mm from the proximal edge of the exposed surface of the active electrode(s), preferably about 1.0 mm to 5.0 mm. Of course, this distance may vary with different voltage ranges, conductive fluids, and depending on the proximity of tissue structures to active and return electrodes. The return electrode will typically have an exposed length in the range of about 1 mm to 20 mm.


A Coblation® treatment device for use according to the present descriptions may use a single active electrode or an array of active electrodes spaced around the distal surface of a catheter or probe. In the latter embodiment, the electrode array usually includes a plurality of independently current-limited and/or power-controlled active electrodes to apply electrical energy selectively to the target tissue while limiting the unwanted application of electrical energy to the surrounding tissue and environment resulting from power dissipation into surrounding electrically conductive fluids, such as blood, normal saline, and the like. The active electrodes may be independently current-limited by isolating the terminals from each other and connecting each terminal to a separate power source that is isolated from the other active electrodes. Alternatively, the active electrodes may be connected to each other at either the proximal or distal ends of the catheter to form a single wire that couples to a power source.


In certain configurations, each individual active electrode in the electrode array may be electrically insulated from all other active electrodes in the array within the instrument and is connected to a power source which is isolated from each of the other active electrodes in the array or to circuitry which limits or interrupts current flow to the active electrode when low resistivity material (e.g., blood, electrically conductive saline irrigant or electrically conductive gel) causes a lower impedance path between the return electrode and the individual active electrode. The isolated power sources for each individual active electrode may be separate power supply circuits having internal impedance characteristics which limit power to the associated active electrode when a low impedance return path is encountered. By way of example, the isolated power source may be a user selectable constant current source. In this embodiment, lower impedance paths will automatically result in lower resistive heating levels since the heating is proportional to the square of the operating current times the impedance. Alternatively, a single power source may be connected to each of the active electrodes through independently actuatable switches, or by independent current limiting elements, such as inductors, capacitors, resistors and/or combinations thereof. The current limiting elements may be provided in the instrument, connectors, cable, controller, or along the conductive path from the controller to the distal tip of the instrument. Alternatively, the resistance and/or capacitance may occur on the surface of the active electrode(s) due to oxide layers which form selected active electrodes (e.g., titanium or a resistive coating on the surface of metal, such as platinum).


The Coblation® device is not limited to electrically isolated active electrodes, or even to a plurality of active electrodes. For example, in certain embodiments the array of active electrodes may be connected to a single lead that extends through the catheter shaft to a power source of high frequency current.


The voltage difference applied between the return electrode(s) and the active electrode(s) will be at high or radio frequency, typically between about 5 kHz and 20 MHz, usually being between about 30 kHz and 2.5 MHz, preferably being between about 50 kHz and 500 kHz, often less than 350 kHz, and often between about 100 kHz and 200 kHz. In some applications, applicant has found that a frequency of about 100 kHz is useful because the tissue impedance is much greater at this frequency. In other applications, such as procedures in or around the heart or head and neck, higher frequencies may be desirable (e.g., 400-600 kHz) to minimize low frequency current flow into the heart or the nerves of the head and neck.


The RMS (root mean square) voltage applied will usually be in the range from about 5 volts to 1000 volts, preferably being in the range from about 10 volts to 500 volts, often between about 150 volts to 400 volts depending on the active electrode size, the operating frequency and the operation mode of the particular procedure or desired effect on the tissue (i.e., contraction, coagulation, cutting or ablation).


Typically, the peak-to-peak voltage for ablation or cutting with a square wave form will be in the range of 10 volts to 2000 volts and preferably in the range of 100 volts to 1800 volts and more preferably in the range of about 300 volts to 1500 volts, often in the range of about 300 volts to 800 volts peak to peak (again, depending on the electrode size, number of electrons, the operating frequency and the operation mode). Lower peak-to-peak voltages will be used for tissue coagulation, thermal heating of tissue, or collagen contraction and will typically be in the range from 50 to 1500, preferably 100 to 1000 and more preferably 120 to 400 volts peak-to-peak (again, these values are computed using a square wave form). Higher peak-to-peak voltages, e.g., greater than about 800 volts peak-to-peak, may be desirable for ablation of harder material, such as bone, depending on other factors, such as the electrode geometries and the composition of the conductive fluid.


As discussed above, the voltage is usually delivered in a series of voltage pulses or alternating current of time varying voltage amplitude with a sufficiently high frequency (e.g., on the order of 5 kHz to 20 MHz) such that the voltage is effectively applied continuously (as compared with, e.g., lasers claiming small depths of necrosis, which are generally pulsed about 10 Hz to 20 Hz). In addition, the duty cycle (i.e., cumulative time in any one-second interval that energy is applied) is on the order of about 50% for the present invention, as compared with pulsed lasers which typically have a duty cycle of about 0.0001%.


The preferred power source of the present invention delivers a high frequency current selectable to generate average power levels ranging from several milliwatts to tens of watts per electrode, depending on the volume of target tissue being treated, and/or the maximum allowed temperature selected for the instrument tip. The power source allows the user to select the voltage level according to the specific requirements of a particular neurosurgery procedure, cardiac surgery, arthroscopic surgery, dermatological procedure, ophthalmic procedures, open surgery or other endoscopic surgery procedure. For cardiac procedures and potentially for neurosurgery, the power source may have an additional filter, for filtering leakage voltages at frequencies below 100 kHz, particularly voltages around 60 kHz. Alternatively, a power source having a higher operating frequency, e.g., 300 kHz to 600 kHz may be used in certain procedures in which stray low frequency currents may be problematic. A description of one suitable power source can be found in commonly assigned U.S. Pat. Nos. 6,142,992 and 6,235,020, the complete disclosure of both patents are incorporated herein by reference for all purposes.


The power source may be current limited or otherwise controlled so that undesired heating of the target tissue or surrounding (non-target) tissue does not occur. In a presently preferred embodiment of the present invention, current limiting inductors are placed in series with each independent active electrode, where the inductance of the inductor is in the range of 10 uH to 50,000 uH, depending on the electrical properties of the target tissue, the desired tissue heating rate and the operating frequency. Alternatively, capacitor-inductor (LC) circuit structures may be employed, as described previously in U.S. Pat. No. 5,697,909, the complete disclosure of which is incorporated herein by reference. Additionally, current-limiting resistors may be selected. Preferably, these resistors will have a large positive temperature coefficient of resistance so that, as the current level begins to rise for any individual active electrode in contact with a low resistance medium (e.g., saline irrigant or blood), the resistance of the current limiting resistor increases significantly, thereby minimizing the power delivery from said active electrode into the low resistance medium (e.g., saline irrigant or blood).


Referring now to FIG. 1, an exemplary electrosurgical system for resection, ablation, coagulation and/or contraction of tissue will now be described in detail. As shown, certain embodiments of the electrosurgical system generally include an electrosurgical probe 20 connected to a power supply 10 for providing high frequency voltage to one or more electrode terminals on probe 20. Probe 20 includes a connector housing 44 at its proximal end, which can be removably connected to a probe receptacle 32 of a probe cable 22. The proximal portion of cable 22 has a connector 34 to couple probe 20 to power supply 10 at receptacle 36. Power supply 10 has an operator controllable voltage level adjustment 38 to change the applied voltage level, which is observable at a voltage level display 40. Power supply 10 also includes one or more foot pedals 24 and a cable 26 which is removably coupled to a receptacle 30 with a cable connector 28. The foot pedal 24 may also include a second pedal (not shown) for remotely adjusting the energy level applied to electrode terminals 42, and a third pedal (also not shown) for switching between an ablation mode and a coagulation mode.


Referring now to FIG. 2, an exemplary electrosurgical system 211 for treatment of tissue in ‘dry fields’ will now be described in detail. Of course, system 211 may also be used in ‘wet field’, i.e., the target site is immersed in electrically conductive fluid. However, this system is particularly useful in ‘dry fields’ where the fluid is preferably delivered through electrosurgical probe to the target site. As shown, electrosurgical system 211 generally comprises an electrosurgical handpiece or probe 210 connected to a power supply 228 for providing high frequency voltage to a target site and a fluid source 221 for supplying electrically conducting fluid 250 to probe 210. The system 211 may also include a vacuum source (not shown) for coupling to a suction lumen disposed in probe 210 (not shown) via a connection tube (not shown) on probe 210 for aspirating the target site, as discussed below in more detail.


As shown, probe 210 generally includes a proximal handle 219 and an elongate shaft 218 having an array 212 of electrode terminals 258 at its distal end. A connecting cable 234 has a connector 226 for electrically coupling the electrode terminals 258 to power supply 228. The electrode terminals 258 are electrically isolated from each other and each of the terminals 258 is connected to an active or passive control network within power supply 228 by means of a plurality of individually insulated conductors (not shown). A fluid supply tube 215 is connected to a fluid tube 214 of probe 210 for supplying electrically conducting fluid 250 to the target site.


Similar to the above embodiment shown in FIG. 1, power supply 228 has an operator controllable voltage level adjustment 230 to change the applied voltage level, which is observable at a voltage level display 232. Power supply 228 also includes first, second and third foot pedals 237, 238, 239 and a cable 236 which is removably coupled to power supply 228. The foot pedals 237, 238, 239 allow the surgeon to remotely adjust the energy level applied to electrode terminals 258. In an exemplary embodiment, first foot pedal 237 is used to place the power supply into the “ablation” mode and second foot pedal 238 places power supply 228 into the “coagulation” mode. The third foot pedal 239 allows the user to adjust the voltage level within the “ablation” mode. In the ablation mode, a sufficient voltage is applied to the electrode terminals to establish the requisite conditions for molecular dissociation of the tissue (i.e., vaporizing a portion of the electrically conductive fluid, ionizing charged particles within the vapor layer and accelerating these charged particles against the tissue). As discussed above, the requisite voltage level for ablation will vary depending on the number, size, shape and spacing of the electrodes, the distance in which the electrodes extend from the support member, etc. Once the surgeon places the power supply in the “ablation” mode, voltage level adjustment 230 or third foot pedal 239 may be used to adjust the voltage level to adjust the degree or aggressiveness of the ablation.


It will be recognized that the voltage and modality of the power supply may be controlled by other input devices. However, applicant has found that foot pedals are convenient methods of controlling the power supply while manipulating the probe during a surgical procedure.


In the coagulation mode, the power supply 228 applies a low enough voltage to the electrode terminals (or the coagulation electrode) to avoid vaporization of the electrically conductive fluid and subsequent molecular dissociation of the tissue. The surgeon may automatically toggle the power supply between the ablation and coagulation modes by alternatively stepping on foot pedals 237, 238, respectively. This allows the surgeon to quickly move between coagulation and ablation in situ, without having to remove his/her concentration from the surgical field or without having to request an assistant to switch the power supply. By way of example, as the surgeon is sculpting soft tissue in the ablation mode, the probe typically will simultaneously seal and/or coagulation small severed vessels within the tissue. However, larger vessels, or vessels with high fluid pressures (e.g., arterial vessels) may not be sealed in the ablation mode. Accordingly, the surgeon can simply step on foot pedal 238, automatically lowering the voltage level below the threshold level for ablation, and apply sufficient pressure onto the severed vessel for a sufficient period of time to seal and/or coagulate the vessel. After this is completed, the surgeon may quickly move back into the ablation mode by stepping on foot pedal 237.


Now referring to FIGS. 3 and 4, an exemplary electrosurgical probe 300 incorporating an active screen electrode 302 is illustrated. Probe 300 may include an elongated shaft 304 which may be flexible or rigid, a handle 306 coupled to the proximal end of shaft 304 and an electrode support member 308 coupled to the distal end of shaft 304. Probe 300 further includes active screen electrode 302 and securing electrode 303. Return electrode 310 is spaced proximally from screen electrode 302 and provides a method for completing the current path between screen electrode 302 and securing electrode 303. As shown, return electrode 310 preferably comprises an annular exposed region of shaft 304 slightly proximal of insulative support member 308, typically about 0.5 to 10 mm and more preferably about 1 to 10 mm. Securing electrode 303 and return electrode 310 are each coupled to respective connectors 328 disposed in handle 306 (as illustrated in FIG. 4) that extend to the proximal end of probe 300, where connectors 328 are suitably electrically connected to a power supply (e.g., power supply 10 in FIG. 1 or power supply 228 in FIG. 2). As shown in FIG. 4, handle 306 defines an inner cavity 326 that houses the electrical connectors 328, and provides a suitable interface for connection to an electrical connecting cable (e.g., cable 22 in FIG. 1 or cable 234 in FIG. 2).


Still referencing FIGS. 3 and 4, in certain embodiments screen electrode 302, securing electrode 303 and insulative support member 308 are configured such that screen electrode 302 and securing electrode 303 are positioned on a lateral side of the shaft 304 (e.g., 90 degrees from the shaft axis) to allow the physician to access tissue that is offset from the axis of the portal or arthroscopic opening into the joint cavity in which the shaft 304 passes during the procedure. To accomplish this, probe 300 may include an electrically insulating cap 320 coupled to the distal end of shaft 304 and having a lateral opening 322 for receiving support member 308, screen electrode 302, and securing electrode 303.


Shaft 304 preferably comprises an electrically conducting material, usually metal, which is selected from the group consisting of tungsten, stainless steel alloys, platinum or its alloys, titanium or its alloys, molybdenum or its alloys, and nickel or its alloys. Shaft 304 may include an electrically insulating jacket 309, which is typically formed as one or more electrically insulating sheaths or coatings, such as polytetrafluoroethylene, polyimide, and the like. The provision of the electrically insulating jacket over the shaft prevents direct electrical contact between these metal elements and any adjacent body structure or the surgeon. Such direct electrical contact between a body structure and an exposed electrode could result in unwanted heating and necrosis of the structure at the point of contact causing necrosis.


The probe 300 further includes a suction connection tube 314 for coupling to a source of vacuum, and an inner suction lumen 312 (FIG. 4) for aspirating excess fluids, tissue fragments, and/or products of ablation (e.g., bubbles) from the target site. Preferably, connection tube 314 and suction lumen 312 are fluidly connected, thereby providing the ability to create a suction pressure in lumen 312 that allows the surgeon to draw loose tissue, e.g., synovial tissue, towards the screen electrode 302. Typically, the vacuum source is a standard hospital pump that provides suction pressure to connection tube 314 and lumen 312. As shown in FIGS. 3 and 4, internal suction lumen 312, which preferably comprises peek tubing, extends from connection tube 314 in handle 306, through shaft 304 to an axial opening 316 in support member 308, through support member 308 to a lateral opening 318 in support member 308. Lateral opening 318 is positioned adjacent to screen electrode 302, which further includes a suction port (not shown) disposed on the surface of screen electrode 302 and fluidly connected to lateral opening 318 for allowing aspiration therethrough, as discussed below in more detail.



FIG. 5 representatively illustrates in more detail the removal of a target tissue by use of an embodiment of electrosurgical probe 50 according to the present disclosure. As shown, the high frequency voltage is sufficient to convert the electrically conductive fluid (not shown) between the target tissue 502 and active electrode terminal(s) 504 into an ionized vapor layer 512 or plasma. As a result of the applied voltage difference between electrode terminal(s) 504 and the target tissue 502 (i.e., the voltage gradient across the plasma layer 512), charged particles 515 in the plasma are accelerated. At sufficiently high voltage differences, these charged particles 515 gain sufficient energy to cause dissociation of the molecular bonds within tissue structures in contact with the plasma field. This molecular dissociation is accompanied by the volumetric removal (i.e., ablative sublimation) of tissue and the production of low molecular weight gases 514, such as oxygen, nitrogen, carbon dioxide, hydrogen and methane. The short range of the accelerated charged particles 515 within the tissue confines the molecular dissociation process to the surface layer to minimize damage and necrosis to the underlying tissue 520.


During the process, the gases 514 will be aspirated through a suction opening and suction lumen to a vacuum source (not shown). In addition, excess electrically conductive fluid, and other fluids (e.g., blood) will be aspirated from the target site 500 to facilitate the surgeon's view. During ablation of the tissue, the residual heat generated by the current flux lines 510 (typically less than 150° C.) between electrode terminals 504 and return electrode 511 will usually be sufficient to coagulate any severed blood vessels at the site. If not, the surgeon may switch the power supply (not shown) into the coagulation mode by lowering the voltage to a level below the threshold for fluid vaporization, as discussed above. This simultaneous hemostasis results in less bleeding and facilitates the surgeon's ability to perform the procedure. Once the blockage has been removed, aeration and drainage are reestablished to allow the sinuses to heal and return to their normal function.


Now referring to FIG. 6, the distal end portion of a preferred embodiment of an electrosurgical probe according to present disclosure is shown. Electrosurgical probe 600 comprises active screen electrode 602 mounted to insulative support member 604 disposed at a distal end of elongate shaft 601. Probe 600 also includes electrically insulating cap 612 coupled to the end of shaft 601 and configured to receive screen electrode 602 and support member 604. In preferred embodiments, securing electrode 606 extends through screen electrode 602 and support member 604 to mechanically secure screen electrode 602 to support member 604 and electrically insulating cap 612. In certain configurations, securing electrodes 606 may be characterized by head 607, leg 608, and tab 610. Preferably, head 607 contacts or engages the superior surface of screen electrode 602, thereby providing an electrical means for the transmission of RF energy between securing electrode 606 and screen electrode 602. Support member 604 may be characterized by channel 609 and slot 611, wherein channel 609 is oriented perpendicularly with respect to the axis of shaft 601 and slot 611 is oriented axially with respect to the axis of shaft 601. Wire 613 extends proximally from slot 611, and is electrically connected to the electrical connectors disposed in the handle of the probe (as discussed above). Return electrode 614 is spaced proximally from screen electrode 602. As discussed above, in this embodiment screen electrode 602 and support member 604 are configured such that screen electrode 602 is positioned on the lateral side of shaft 601 (e.g., 90 degrees from the shaft axis) to allow the physician to access tissue that is offset from the axis of the port or arthroscopic opening into the joint cavity in which shaft 601 passes during the procedure.


Referring now to FIG. 7A, an embodiment of securing electrode 606 is shown. Securing electrode 606 may be formed with a conductive material such as tungsten, and the shape and profile of securing electrode 606 may be manufactured via etching, laser cutting, or injection molding. In certain configurations, securing electrode 606 may be characterized by saw tooth pattern 615 on the superior plasma forming surface of securing electrode 606. The added edges formed on securing electrodes 606 by saw tooth pattern 615 in this configuration may result in increased current density and thus promote the formation of improved zones for plasma formation and RF ablation.


Referring now to FIG. 7B, screen electrode 602 will comprise a conductive material, such as tungsten, titanium, molybdenum, stainless steel, aluminum, gold, copper or the like. Screen electrode 602 will usually have a diameter in the range of about 0.5 to 8 mm, preferably about 1 to 4 mm, and a thickness of about 0.05 to about 2.5 mm, preferably about 0.1 to 1 mm. Screen electrode 602 may have a variety of different shapes, such as the shape shown in FIG. 7B. Screen electrode may have slots 616 therethrough, and may comprise suction opening 618 having sizes and configurations that may vary depending on the particular application. Suction opening 618 will typically be large enough to allow ablated tissue fragments to pass through into suction lumen port 620 (see FIG. 8), typically being about 2 to 30 mils in diameter, preferably about 5 to 20 mils in diameter. In some applications, it may be desirable to only aspirate fluid and the gaseous products of ablation (e.g., bubbles) so that the holes may be much smaller, e.g., on the order of less than 10 mils, often less than 5 mils. In certain configurations, suction opening 618 may be formed in the shape of a zigzag or lightning bolt.


Referring now to FIG. 8, insulative electrode support member 604 preferably comprises an inorganic material, such as glass, ceramic, silicon nitride, alumina or the like, that has been formed with lateral and axial suction lumen openings 620, 622, and with one or more lateral axial passages 624 for receiving electrical wires 613. Wires 613 extend from electrical connectors (i.e., electrical connectors 328 in FIG. 4), through shaft 601 and passages 624 in support member 604, terminating in proximity to slots 611 and tabs 610 of securing electrodes 606. Wires 613 are electrically connected to securing electrodes 606 (e.g., by a laser welding process) thereby electrically coupling securing electrodes 606 and screen electrode 602 to a high frequency power supply. Referring to FIGS. 6, 7B, and 8, legs 608 may extend through slots 616 of screen electrode 602 and channels 609 of support member 604, and tabs 610 may be inserted into slots 611 of support member 604 such that tabs 610 interfere or engage with a portion of support member 604. The placement of securing electrodes 606 such that tabs 610 are inserted into slots 611 creates a mechanical method of joining securing electrodes 606 to support member 604 and thereby prevents securing electrodes 606 from moving axially with respect to shaft 601 and support member 604. Additionally, the method of mechanical securement results in the capture of screen electrode 602 between securing electrodes 606 and support member 604. Further, as described above the contact between heads 607 of securing electrodes 606 and screen electrode 602 provides a method to electrically transmit RF energy through support member 604 to screen electrode 602.


In additional embodiments, the mechanical method of joining may comprise complementary helical threads cut in channels 609 of support member 604 and respectively in legs 608 of securing electrodes 606, wherein legs 608 of securing electrodes 606 are operable to threadingly engage channels 609 of support member 604. Additional embodiments of the present disclosure may include configurations where tabs 610 are formed in a barb or arrowhead shape and are disposed in interference with support member 604. Moreover, in additional embodiments tabs 610 may be completely enclosed within support member 604, and may be further secured to support member 604 by epoxy.


Referring now to FIGS. 9 and 10, the distal end portion of representative probe 600 is shown with at least two bilateral securing electrodes 606 thereon. In this configuration, securing electrodes 606 may be oriented symmetrically about the central axis of shaft 601, and may thereby allow for creation of a zone for RF ablation or plasma chamber 1000 between the symmetrically oriented bilateral securing electrodes 606 as well as between securing electrodes 606 and screen electrode 602 (see i.e., FIG. 10). Incorporation of symmetrical securing electrodes 606 may allow for the creation of a three dimensional zone represented by plasma zone 1000 for carrying out RF ablation.


Other modifications and variations can be made to disclose embodiments without departing from the subject invention as defined in the following claims. For example, it should be noted that the invention is not limited to an electrode array comprising a plurality of electrode terminals. The invention could utilize a plurality of return electrodes, e.g., in a bipolar array or the like. In addition, depending on other conditions, such as the peak-to-peak voltage, electrode diameter, etc., a single electrode terminal may be sufficient to contract collagen tissue, ablate tissue, or the like.


In addition, the active and return electrodes may both be located on a distal tissue treatment surface adjacent to each other. The active and return electrodes may be located in active/return electrode pairs, or one or more return electrodes may be located on the distal tip together with a plurality of electrically isolated electrode terminals. The proximal return electrode may or may not be employed in these embodiments. For example, if it is desired to maintain the current flux lines around the distal tip of the probe, the proximal return electrode will not be desired.


While preferred embodiments of this invention have been shown and described, modifications thereof can be made by one skilled in the art without departing from the scope or teaching herein. The embodiments described herein are exemplary only and are not limiting. Because many varying and different embodiments may be made within the scope of the present teachings, including equivalent structures or materials hereafter thought of, and because many modifications may be made in the embodiments herein detailed in accordance with the descriptive requirements of the law, it is to be understood that the details herein are to be interpreted as illustrative and not in a limiting sense.

Claims
  • 1. An electrosurgical instrument for removing tissue from a target site within or on a patient's body comprising: a shaft having a proximal end and a distal end portion;an electrode assembly comprising a substantially flat active screen electrode positioned on the distal end portion of the shaft, at least one return electrode positioned on the shaft and spaced away from the active electrode, and at least one securing electrode positioned on the distal end portion of the shaft and disposed through a screen slot in the screen electrode, the at least one securing electrode comprising an electrode head that electrically connects the at least one securing electrode to the screen electrode;wherein the at least one securing electrode further comprises a leg extending from the electrode head, and a tab extending from the leg;an electrically insulating support member upon which the screen electrode is mounted, the support member mechanically interfering with and engaging a portion of the tab of the at least one securing electrode, wherein the electrode head has an elongate surface extending beyond the screen slot such that the combination of the electrode head and the tab mechanically act to fixedly secure the screen electrode to the support member and maintain electrical connection between the at least one securing electrode and the screen electrode; andat least one electrical connector extending through the shaft, wherein the at least one securing electrode is electrically coupled to the at least one electrical connector at the tab.
  • 2. The instrument of claim 1, wherein the tab mechanically engages a corresponding axial slot disposed along an outer surface of the support member.
  • 3. The instrument of claim 2, wherein the leg is received within a corresponding channel disposed along the outer surface of the support member.
  • 4. The instrument of claim 3, wherein the electrode head engages a superior surface of the active screen electrode, and the leg is received into the corresponding channel through the screen electrode slot.
  • 5. The instrument of claim 1, the at least one securing electrode having a saw tooth pattern on a superior surface.
  • 6. The instrument of claim 1 further comprising an aspiration lumen within the shaft having a distal opening coupled to the screen electrode to inhibit clogging of the lumen, wherein the support member has an axial opening in communication with the lumen and a lateral opening in contact with the screen electrode.
  • 7. The instrument of claim 1 wherein the screen electrode and the at least one securing electrode are configured to be brought adjacent a tissue structure immersed in electrically conductive fluid and the electrically conductive fluid completes a conduction path between the screen electrode, the at least one securing electrode and the return electrode.
  • 8. The instrument of claim 7, wherein upon the application of a sufficiently high frequency voltage between the screen electrode, the at least one securing electrode, and the return electrode the conductive fluid vaporizes in a thin layer over at least a portion of the screen electrode and the at least one securing electrode and induces the discharge of energy from the vapor layer.
  • 9. The instrument of claim 8 wherein the discharge of energy from the vapor layer is sufficient to form a plasma.
  • 10. The instrument of claim 8, wherein the vapor layer is configured to contact the tissue structure and is capable of ablating a portion of the tissue structure.
  • 11. An electrosurgical instrument for removing tissue from a target site within or on a patient's body comprising: a shaft having proximal and distal end portions;an electrode assembly on the distal end portion, the electrode assembly comprising a substantially flat active screen electrode, a return electrode spaced from the active screen electrode, and bilateral securing electrodes electrically coupled to the active screen electrode and securing the active screen electrode to the shaft;wherein each securing electrode comprises an electrode head, a leg extending from the head and a tab extending from the leg, wherein the electrode head has an elongate surface that engages and secures the screen electrode, and wherein the electrode head electrically connects each securing electrode to the screen electrode;an insulative support body operable to support the active screen electrode and engage the tabs of the bilateral securing electrodes so as cooperate with the electrode head to mechanically secure the screen electrode to the support body; andelectrical connectors extending through the shaft, the electrical connectors operable to couple the bilateral securing electrodes with a high frequency power supply.
  • 12. The instrument of claim 11 wherein the tabs engage axial slots in the support body.
  • 13. The instrument of claim 11 wherein the bilateral securing electrodes each have a superior surface characterized by a plurality of teeth.
  • 14. The instrument of claim 11, wherein the bilateral securing electrodes are disposed in a symmetric orientation to one another about a central axis of the shaft.
  • 15. The instrument of claim 14, wherein the symmetric orientation of the bilateral securing electrodes defines a plasma chamber between the bilateral securing electrodes.
US Referenced Citations (538)
Number Name Date Kind
2050904 Trice Aug 1936 A
2056377 Wappler Oct 1939 A
2275167 Bierman Mar 1942 A
3633425 Sanford Jan 1972 A
3699967 Anderson Oct 1972 A
3812858 Oringer May 1974 A
3815604 O'Malley et al. Jun 1974 A
3828780 Morrison, Jr. et al. Aug 1974 A
3901242 Storz Aug 1975 A
3920021 Hiltebrandt Nov 1975 A
3939839 Curtiss Feb 1976 A
3945375 Banko Mar 1976 A
3970088 Morrison Jul 1976 A
4033351 Hetzel Jul 1977 A
4040426 Morrison, Jr. Aug 1977 A
4043342 Morrison, Jr. Aug 1977 A
4074718 Morrison, Jr. Feb 1978 A
4092986 Schneiderman Jun 1978 A
4116198 Roos Sep 1978 A
4181131 Ogiu Jan 1980 A
4184492 Meinke et al. Jan 1980 A
4202337 Hren et al. May 1980 A
4203444 Bonnell et al. May 1980 A
4228800 Degler, Jr. et al. Oct 1980 A
4232676 Herczog Nov 1980 A
4240441 Khalil Dec 1980 A
4248231 Herczog et al. Feb 1981 A
4269174 Adair May 1981 A
4326529 Doss et al. Apr 1982 A
4381007 Doss Apr 1983 A
4411266 Cosman Oct 1983 A
4429694 McGreevy Feb 1984 A
4474179 Koch Oct 1984 A
4476862 Pao Oct 1984 A
4483338 Bloom et al. Nov 1984 A
4532924 Auth et al. Aug 1985 A
4548207 Reimels Oct 1985 A
4567890 Ohta et al. Feb 1986 A
4582057 Auth et al. Apr 1986 A
4590934 Malis et al. May 1986 A
4593691 Lindstrom et al. Jun 1986 A
4641649 Walinsky Feb 1987 A
4658817 Hardy Apr 1987 A
4660571 Hess et al. Apr 1987 A
4674499 Pao Jun 1987 A
4682596 Bales et al. Jul 1987 A
4706667 Roos Nov 1987 A
4709698 Johnston et al. Dec 1987 A
4719914 Johnson Jan 1988 A
4727874 Bowers et al. Mar 1988 A
4736743 Daikuzono Apr 1988 A
4737678 Hasegawa Apr 1988 A
4762128 Rosenbluth Aug 1988 A
4765331 Petruzzi et al. Aug 1988 A
4785806 Deckelbaum Nov 1988 A
4785823 Eggers et al. Nov 1988 A
4805616 Pao Feb 1989 A
4813429 Eshel et al. Mar 1989 A
4823791 D'Amelio et al. Apr 1989 A
4827911 Broadwin et al. May 1989 A
4832048 Cohen May 1989 A
4860752 Turner et al. Aug 1989 A
4903696 Stasz et al. Feb 1990 A
4907589 Cosman Mar 1990 A
4920978 Colvin May 1990 A
4931047 Broadwin et al. Jun 1990 A
4936281 Stasz Jun 1990 A
4936301 Rexroth et al. Jun 1990 A
4940064 Desai Jul 1990 A
4943290 Rexroth et al. Jul 1990 A
4955377 Lennox et al. Sep 1990 A
4966597 Cosman Oct 1990 A
4967765 Turner et al. Nov 1990 A
4968314 Michaels Nov 1990 A
4976709 Sand Dec 1990 A
4976711 Parins et al. Dec 1990 A
4979948 Geddes et al. Dec 1990 A
4998933 Eggers et al. Mar 1991 A
5007437 Sterzer Apr 1991 A
5007908 Rydell Apr 1991 A
5009656 Reimels Apr 1991 A
5035696 Rydell Jul 1991 A
5037421 Boutacoff et al. Aug 1991 A
5047026 Rydell Sep 1991 A
5047027 Rydell Sep 1991 A
5057105 Malone et al. Oct 1991 A
5057106 Kasevich et al. Oct 1991 A
5061266 Hakky Oct 1991 A
5078717 Parins et al. Jan 1992 A
5080660 Buelna Jan 1992 A
5083565 Parins Jan 1992 A
5084044 Quint Jan 1992 A
5084045 Helenowski Jan 1992 A
5085659 Rydell Feb 1992 A
5088997 Delahuerga et al. Feb 1992 A
5092339 Geddes et al. Mar 1992 A
5093877 Aita et al. Mar 1992 A
5098431 Rydell Mar 1992 A
5099840 Goble Mar 1992 A
5102410 Dressel Apr 1992 A
5103804 Abele et al. Apr 1992 A
5108391 Flachenecker et al. Apr 1992 A
RE33925 Bales et al. May 1992 E
5112330 Nishigaki et al. May 1992 A
5122138 Manwaring Jun 1992 A
5125928 Parins et al. Jun 1992 A
5137530 Sand Aug 1992 A
5147354 Boutacoff et al. Sep 1992 A
5151098 Loertscher Sep 1992 A
5156151 Imran Oct 1992 A
5167659 Ohtomo et al. Dec 1992 A
5171311 Rydell et al. Dec 1992 A
5176528 Fry et al. Jan 1993 A
5178620 Eggers et al. Jan 1993 A
5190517 Zieve et al. Mar 1993 A
5191883 Lennox et al. Mar 1993 A
5192280 Parins Mar 1993 A
5195959 Smith Mar 1993 A
5197466 Marchosky et al. Mar 1993 A
5197963 Parins Mar 1993 A
5207675 Canady May 1993 A
5217455 Tan Jun 1993 A
5217457 Delahuerga et al. Jun 1993 A
5217459 Kamerling Jun 1993 A
5230334 Klopotek Jul 1993 A
5234428 Kaufman Aug 1993 A
5246438 Langberg Sep 1993 A
5249585 Turner et al. Oct 1993 A
5261410 Alfano et al. Nov 1993 A
5267994 Gentelia et al. Dec 1993 A
5267997 Farin et al. Dec 1993 A
5269794 Rexroth Dec 1993 A
5273524 Fox et al. Dec 1993 A
5277201 Stern Jan 1994 A
5277696 Hagen Jan 1994 A
5279299 Imran Jan 1994 A
5281216 Klicek Jan 1994 A
5281218 Imran Jan 1994 A
5282797 Chess Feb 1994 A
5282799 Rydell Feb 1994 A
5290273 Tan Mar 1994 A
5290282 Casscells Mar 1994 A
5293868 Nardella Mar 1994 A
5295956 Bales et al. Mar 1994 A
5300069 Hunsberger et al. Apr 1994 A
5300099 Rudie Apr 1994 A
5301687 Wong et al. Apr 1994 A
5304169 Sand Apr 1994 A
5304170 Green Apr 1994 A
5306238 Fleenor Apr 1994 A
5312395 Tan et al. May 1994 A
5312400 Bales et al. May 1994 A
5314406 Arias et al. May 1994 A
5318563 Malis et al. Jun 1994 A
5322507 Costello et al. Jun 1994 A
5324254 Phillips Jun 1994 A
5330470 Hagen Jul 1994 A
5330518 Neilson et al. Jul 1994 A
5334140 Phillips Aug 1994 A
5334183 Wuchinich Aug 1994 A
5334193 Nardella Aug 1994 A
5335668 Nardella Aug 1994 A
5336217 Buys et al. Aug 1994 A
5336220 Ryan et al. Aug 1994 A
5342357 Nardella Aug 1994 A
5348554 Imran et al. Sep 1994 A
5366443 Eggers Nov 1994 A
5370642 Keller Dec 1994 A
5370644 Langberg Dec 1994 A
5370675 Edwards et al. Dec 1994 A
5374261 Yoon Dec 1994 A
5374265 Sand Dec 1994 A
5375588 Yoon Dec 1994 A
5380277 Phillips Jan 1995 A
5380316 Aita Jan 1995 A
5383876 Nardella Jan 1995 A
5383917 Desai et al. Jan 1995 A
5389096 Aita Feb 1995 A
5395312 Desai Mar 1995 A
5395363 Billings et al. Mar 1995 A
5400267 Denen et al. Mar 1995 A
5401272 Perkins Mar 1995 A
5403311 Abele et al. Apr 1995 A
5405376 Mulier et al. Apr 1995 A
5417687 Nardella et al. May 1995 A
5419767 Eggers et al. May 1995 A
5423803 Tankovich Jun 1995 A
5423810 Goble et al. Jun 1995 A
5423844 Miller Jun 1995 A
5423882 Jackman et al. Jun 1995 A
5431649 Mulier et al. Jul 1995 A
5433708 Nichols et al. Jul 1995 A
5436566 Thompson et al. Jul 1995 A
5437662 Nardella Aug 1995 A
5437664 Cohen et al. Aug 1995 A
5438302 Goble Aug 1995 A
5441499 Fritzsch Aug 1995 A
5445634 Keller Aug 1995 A
5451224 Goble et al. Sep 1995 A
5454809 Janssen Oct 1995 A
5458596 Lax et al. Oct 1995 A
5462545 Wang et al. Oct 1995 A
5484435 Fleenor et al. Jan 1996 A
5487385 Avitall Jan 1996 A
5490850 Ellman et al. Feb 1996 A
5496312 Klicek Mar 1996 A
5496314 Eggers Mar 1996 A
5496317 Goble et al. Mar 1996 A
5505710 Dorsey, III Apr 1996 A
5514130 Baker May 1996 A
5520685 Wojciechowicz May 1996 A
5536267 Edwards et al. Jul 1996 A
5542928 Evans et al. Aug 1996 A
5545161 Imran Aug 1996 A
5554152 Aita Sep 1996 A
5556397 Long et al. Sep 1996 A
5562703 Desai Oct 1996 A
5567890 Lindberg et al. Oct 1996 A
5569242 Lax et al. Oct 1996 A
5571100 Goble et al. Nov 1996 A
5579764 Goldreyer Dec 1996 A
5584872 LaFontaine et al. Dec 1996 A
5607421 Jeevanandam et al. Mar 1997 A
5609151 Mulier et al. Mar 1997 A
5626576 Janssen May 1997 A
5633578 Eggers et al. May 1997 A
5643255 Organ Jul 1997 A
5647869 Goble et al. Jul 1997 A
5653692 Masterson et al. Aug 1997 A
5660836 Knowlton Aug 1997 A
5662680 Desai Sep 1997 A
5676693 LaFontaine et al. Oct 1997 A
5681282 Eggers et al. Oct 1997 A
5681308 Edwards et al. Oct 1997 A
5683366 Eggers et al. Nov 1997 A
5688267 Panescu et al. Nov 1997 A
5697281 Eggers et al. Dec 1997 A
5697536 Eggers et al. Dec 1997 A
5697882 Eggers et al. Dec 1997 A
5697909 Eggers et al. Dec 1997 A
5700262 Acosta et al. Dec 1997 A
5713896 Nardella Feb 1998 A
5725524 Mulier et al. Mar 1998 A
5743870 Edwards Apr 1998 A
5743903 Stern et al. Apr 1998 A
5746746 Garito et al. May 1998 A
5749869 Lindenmeier et al. May 1998 A
5755753 Knowlton May 1998 A
5766153 Eggers et al. Jun 1998 A
5769843 Abela et al. Jun 1998 A
5769847 Panescu et al. Jun 1998 A
5782795 Bays Jul 1998 A
5785705 Baker Jul 1998 A
5800429 Edwards Sep 1998 A
5800431 Brown Sep 1998 A
5807384 Mueller Sep 1998 A
5807395 Mulier et al. Sep 1998 A
5810764 Eggers et al. Sep 1998 A
5810802 Panescu et al. Sep 1998 A
5810809 Rydell Sep 1998 A
5836875 Webster, Jr. Nov 1998 A
5843019 Eggers et al. Dec 1998 A
5843078 Sharkey Dec 1998 A
5855277 Apps et al. Jan 1999 A
5860951 Eggers Jan 1999 A
5860974 Abele Jan 1999 A
5860975 Goble et al. Jan 1999 A
5871469 Eggers et al. Feb 1999 A
5871524 Knowlton Feb 1999 A
5873855 Eggers et al. Feb 1999 A
5876398 Mulier et al. Mar 1999 A
5885277 Korth Mar 1999 A
5888198 Eggers et al. Mar 1999 A
5891095 Eggers et al. Apr 1999 A
5891134 Goble et al. Apr 1999 A
5893848 Negus et al. Apr 1999 A
5895386 Odell et al. Apr 1999 A
5897553 Mulier Apr 1999 A
5902272 Eggers et al. May 1999 A
5904681 West, Jr. May 1999 A
5906613 Mulier et al. May 1999 A
5919219 Knowlton Jul 1999 A
5944715 Goble et al. Aug 1999 A
5954716 Sharkey et al. Sep 1999 A
5964754 Osypka Oct 1999 A
5976127 Lax Nov 1999 A
5980516 Mulier et al. Nov 1999 A
5980545 Pacala et al. Nov 1999 A
5984919 Hilal et al. Nov 1999 A
6004319 Goble et al. Dec 1999 A
6007533 Casscells et al. Dec 1999 A
6007570 Sharkey et al. Dec 1999 A
6013076 Goble et al. Jan 2000 A
6015406 Goble et al. Jan 2000 A
6016809 Mulier et al. Jan 2000 A
6024733 Eggers et al. Feb 2000 A
6027501 Goble et al. Feb 2000 A
6030383 Benderev Feb 2000 A
6032673 Savage et al. Mar 2000 A
6032674 Eggers et al. Mar 2000 A
6039734 Goble et al. Mar 2000 A
6042580 Simpson Mar 2000 A
6045532 Eggers et al. Apr 2000 A
6047700 Eggers et al. Apr 2000 A
6053172 Hovda et al. Apr 2000 A
6056746 Goble et al. May 2000 A
6063079 Hovda et al. May 2000 A
6063081 Mulier et al. May 2000 A
6066134 Eggers et al. May 2000 A
6068628 Fanton et al. May 2000 A
6074386 Goble et al. Jun 2000 A
6090106 Goble et al. Jul 2000 A
6091995 Ingle et al. Jul 2000 A
6093186 Goble et al. Jul 2000 A
6096037 Mulier et al. Aug 2000 A
6102046 Weinstein et al. Aug 2000 A
6105581 Eggers et al. Aug 2000 A
6109268 Thapliyal et al. Aug 2000 A
6110169 Mueller et al. Aug 2000 A
6117109 Eggers et al. Sep 2000 A
6126682 Sharkey et al. Oct 2000 A
6142992 Cheng et al. Nov 2000 A
6149620 Baker et al. Nov 2000 A
6152923 Ryan Nov 2000 A
6156031 Aita et al. Dec 2000 A
6159194 Eggers et al. Dec 2000 A
6159208 Hovda et al. Dec 2000 A
6168593 Sharkey et al. Jan 2001 B1
6174309 Wrublewski et al. Jan 2001 B1
6179824 Eggers et al. Jan 2001 B1
6179836 Eggers et al. Jan 2001 B1
6183469 Thapliyal et al. Feb 2001 B1
6190381 Olsen et al. Feb 2001 B1
6203542 Ellsberry et al. Mar 2001 B1
6210402 Olsen et al. Apr 2001 B1
6210405 Goble et al. Apr 2001 B1
6214001 Casscells et al. Apr 2001 B1
6217575 DeVore et al. Apr 2001 B1
6224592 Eggers et al. May 2001 B1
6228078 Eggers May 2001 B1
6228081 Goble May 2001 B1
6235020 Cheng et al. May 2001 B1
6235023 Lee et al. May 2001 B1
6237604 Burnside et al. May 2001 B1
6238391 Olsen et al. May 2001 B1
6238393 Mulier et al. May 2001 B1
6254600 Willink et al. Jul 2001 B1
6261286 Goble et al. Jul 2001 B1
6261311 Sharkey et al. Jul 2001 B1
6264650 Hovda Jul 2001 B1
6264652 Eggers et al. Jul 2001 B1
6267757 Aita et al. Jul 2001 B1
6270460 McCartan et al. Aug 2001 B1
6277112 Underwood et al. Aug 2001 B1
6280441 Ryan Aug 2001 B1
6283961 Underwood et al. Sep 2001 B1
6293942 Goble et al. Sep 2001 B1
6296636 Cheng et al. Oct 2001 B1
6296638 Davison et al. Oct 2001 B1
6302903 Mulier et al. Oct 2001 B1
6306134 Goble et al. Oct 2001 B1
6308089 von der Ruhr et al. Oct 2001 B1
6309387 Eggers et al. Oct 2001 B1
6312408 Eggers et al. Nov 2001 B1
6312429 Butbank et al. Nov 2001 B1
6315774 Daniel et al. Nov 2001 B1
6322494 Bullivant et al. Nov 2001 B1
6322549 Eggers et al. Nov 2001 B1
6325799 Goble Dec 2001 B1
6327505 Medhkour et al. Dec 2001 B1
6328736 Mulier et al. Dec 2001 B1
6336926 Goble Jan 2002 B1
6346107 Cucin Feb 2002 B1
6355006 Ryaby et al. Mar 2002 B1
6355032 Hovda et al. Mar 2002 B1
6358248 Mulier et al. Mar 2002 B1
6363937 Hovda et al. Apr 2002 B1
6364877 Goble et al. Apr 2002 B1
6379350 Sharkey et al. Apr 2002 B1
6379351 Thapliyal et al. Apr 2002 B1
6391025 Weinstein et al. May 2002 B1
6391028 Fanton et al. May 2002 B1
6398781 Goble et al. Jun 2002 B1
6409724 Penny et al. Jun 2002 B1
6416507 Eggers et al. Jul 2002 B1
6416508 Eggers et al. Jul 2002 B1
6416509 Goble et al. Jul 2002 B1
6432103 Ellsberry et al. Aug 2002 B1
6432105 Ellman et al. Aug 2002 B1
6468274 Alleyne et al. Oct 2002 B1
6468275 Wampler et al. Oct 2002 B1
6482201 Olsen et al. Nov 2002 B1
6482202 Goble et al. Nov 2002 B1
6491690 Gobel et al. Dec 2002 B1
6497705 Comben Dec 2002 B2
6497706 Burbank et al. Dec 2002 B1
6510854 Gobel Jan 2003 B2
6514250 Jahns et al. Feb 2003 B1
6517498 Burbank et al. Feb 2003 B1
6517535 Edwards Feb 2003 B2
6530922 Cosman Mar 2003 B2
6540741 Underwood et al. Apr 2003 B1
6557559 Eggers et al. May 2003 B1
6575968 Eggers et al. Jun 2003 B1
6575969 Rittman, III et al. Jun 2003 B1
6578579 Burnside Jun 2003 B2
6582423 Thapliyal et al. Jun 2003 B1
6589237 Woloszko et al. Jul 2003 B2
6595990 Weinstein et al. Jul 2003 B1
6597950 Linder et al. Jul 2003 B2
6605085 Edwards Aug 2003 B1
6610059 West, Jr. Aug 2003 B1
6620156 Garito et al. Sep 2003 B1
6632193 Davison et al. Oct 2003 B1
6632220 Eggers et al. Oct 2003 B1
6632230 Barry Oct 2003 B2
6663628 Peters Dec 2003 B2
6695839 Sharkey et al. Feb 2004 B2
6699206 Burbank et al. Mar 2004 B2
6699244 Carranza et al. Mar 2004 B2
6702810 McClurken et al. Mar 2004 B2
6746447 Davison et al. Jun 2004 B2
6749604 Eggers et al. Jun 2004 B1
6749608 Garito et al. Jun 2004 B2
6763836 Tasto et al. Jul 2004 B2
6770071 Woloszko et al. Aug 2004 B2
6780178 Palanker et al. Aug 2004 B2
6780180 Goble et al. Aug 2004 B1
6796982 Carmel et al. Sep 2004 B2
6802842 Ellman et al. Oct 2004 B2
6805130 Tasto et al. Oct 2004 B2
6827725 Batchelor et al. Dec 2004 B2
6832996 Woloszko et al. Dec 2004 B2
6837887 Woloszko et al. Jan 2005 B2
6837888 Ciarrocca et al. Jan 2005 B2
6855143 Davison et al. Feb 2005 B2
6896674 Woloszko et al. May 2005 B1
6904303 Phan et al. Jun 2005 B2
6920883 Bessette et al. Jul 2005 B2
6929640 Underwood et al. Aug 2005 B1
6949096 Davison et al. Sep 2005 B2
6960204 Eggers et al. Nov 2005 B2
6974453 Woloszko et al. Dec 2005 B2
6979332 Adams Dec 2005 B2
6984231 Goble et al. Jan 2006 B2
6991631 Woloszko et al. Jan 2006 B2
7004941 Tvinnereim et al. Feb 2006 B2
7041102 Truckai et al. May 2006 B2
7070596 Woloszko et al. Jul 2006 B1
7090672 Underwood et al. Aug 2006 B2
7094215 Davison et al. Aug 2006 B2
7104986 Hovda et al. Sep 2006 B2
7131969 Hovda et al. Nov 2006 B1
7150747 McDonald et al. Dec 2006 B1
7169143 Eggers et al. Jan 2007 B2
7179255 Lettice et al. Feb 2007 B2
7184811 Phan et al. Feb 2007 B2
7186234 Dahla et al. Mar 2007 B2
7192428 Eggers et al. Mar 2007 B2
7201750 Eggers et al. Apr 2007 B1
7217268 Eggers et al. May 2007 B2
7241293 Davison Jul 2007 B2
7258690 Sutton et al. Aug 2007 B2
7261712 Burbank et al. Aug 2007 B2
7270658 Woloszko et al. Sep 2007 B2
7270659 Hovda et al. Sep 2007 B2
7270661 Dahla et al. Sep 2007 B2
7276063 Davison et al. Oct 2007 B2
7297143 Woloszko et al. Nov 2007 B2
7297145 Ormsby et al. Nov 2007 B2
7318823 Sharps et al. Jan 2008 B2
7331956 Hovda et al. Feb 2008 B2
RE40156 Sharps et al. Mar 2008 E
7357798 Sharps et al. Apr 2008 B2
7387625 Hovda et al. Jun 2008 B2
7419488 Ciarrocca et al. Sep 2008 B2
7429260 Underwood et al. Sep 2008 B2
7429262 Woloszko et al. Sep 2008 B2
7435247 Woloszko et al. Oct 2008 B2
7488295 Burbank et al. Feb 2009 B2
7776034 Kampa Aug 2010 B2
7819863 Eggers et al. Oct 2010 B2
8038670 McClurken Oct 2011 B2
20010023347 Sharkey et al. Sep 2001 A1
20010025177 Woloszko et al. Sep 2001 A1
20020029036 Goble et al. Mar 2002 A1
20020049438 Sharkey et al. Apr 2002 A1
20020072739 Lee et al. Jun 2002 A1
20030013986 Saadat Jan 2003 A1
20030028189 Woloszko et al. Feb 2003 A1
20030088245 Woloszko et al. May 2003 A1
20030130711 Pearson et al. Jul 2003 A1
20030158545 Hovda et al. Aug 2003 A1
20030171743 Tasto et al. Sep 2003 A1
20030208194 Hovda et al. Nov 2003 A1
20030208196 Stone Nov 2003 A1
20030212396 Eggers et al. Nov 2003 A1
20040116922 Hovda et al. Jun 2004 A1
20040127893 Hovda Jul 2004 A1
20040230190 Dahla et al. Nov 2004 A1
20050004634 Hovda et al. Jan 2005 A1
20050119650 Sanders et al. Jun 2005 A1
20050131402 Ciarrocca et al. Jun 2005 A1
20050187543 Underwood et al. Aug 2005 A1
20050234439 Underwood et al. Oct 2005 A1
20050251134 Woloszko et al. Nov 2005 A1
20050261754 Woloszko et al. Nov 2005 A1
20050288665 Woloszko et al. Dec 2005 A1
20060036237 Davison et al. Feb 2006 A1
20060095031 Ormsby May 2006 A1
20060178670 Woloszko et al. Aug 2006 A1
20060189971 Eggers et al. Aug 2006 A1
20060253117 Hovda et al. Nov 2006 A1
20060259025 Dahla Nov 2006 A1
20070010808 Dahla Jan 2007 A1
20070106288 Woloszko et al. May 2007 A1
20070112348 Eggers et al. May 2007 A1
20070129715 Eggers et al. Jun 2007 A1
20070149966 Dahla et al. Jun 2007 A1
20070161981 Sanders et al. Jul 2007 A1
20070179497 Eggers et al. Aug 2007 A1
20070208334 Woloszko et al. Sep 2007 A1
20070208335 Woloszko et al. Sep 2007 A1
20070213700 Davison et al. Sep 2007 A1
20070282323 Woloszko et al. Dec 2007 A1
20080021447 Davison et al. Jan 2008 A1
20080167645 Woloszko Jul 2008 A1
20080167646 Godara et al. Jul 2008 A1
20080234673 Marion et al. Sep 2008 A1
20080300590 Horne et al. Dec 2008 A1
20090069807 Eggers et al. Mar 2009 A1
20090138011 Epstein May 2009 A1
20090209958 Davison et al. Aug 2009 A1
20100152724 Marion et al. Jun 2010 A1
20100204690 Bigley et al. Aug 2010 A1
20110077643 Dahla et al. Mar 2011 A1
20110077646 Dahla et al. Mar 2011 A1
20110270242 Marion Nov 2011 A1
Foreign Referenced Citations (113)
Number Date Country
2521719 Nov 1976 DE
3930451 Mar 1991 DE
4425015 Jan 1996 DE
296 09 350 Aug 1996 DE
195 37 084 Apr 1997 DE
296 19 029 Apr 1997 DE
19850671 May 1999 DE
10254668 Jun 2004 DE
69822877 Jan 2005 DE
202008000276 Jun 2008 DE
102009057921 Jun 2010 DE
0 502 268 Sep 1992 EP
0 515 867 Dec 1992 EP
543123 May 1993 EP
0 597 463 May 1994 EP
774926 Mar 1995 EP
0 650 701 May 1995 EP
0703461 Mar 1996 EP
0740926 Nov 1996 EP
0 754 437 Jan 1997 EP
923907 Jun 1999 EP
0 694 290 Nov 2000 EP
1149564 Oct 2001 EP
1041933 Mar 2004 EP
2313949 Jan 1977 FR
2037167 Jul 1980 GB
2 308 979 Jul 1997 GB
2 308 980 Jul 1997 GB
2 308 981 Jul 1997 GB
2 327 350 Jan 1999 GB
2 327 351 Jan 1999 GB
2 327 352 Jan 1999 GB
2331247 May 1999 GB
2379878 Mar 2003 GB
2408936 Jun 2005 GB
57-57802 Apr 1982 JP
57-117843 Jul 1982 JP
57-183850 Nov 1982 JP
63-40099 Aug 1988 JP
9-501328 Feb 1997 JP
9003152 Apr 1990 WO
9007303 Jul 1990 WO
9113650 Sep 1991 WO
9221278 Dec 1992 WO
9313816 Jul 1993 WO
9320747 Oct 1993 WO
9403134 Feb 1994 WO
9404220 Mar 1994 WO
9408654 Apr 1994 WO
9410924 May 1994 WO
9414383 Jul 1994 WO
9426228 Nov 1994 WO
9505780 Mar 1995 WO
9505781 Mar 1995 WO
9505867 Mar 1995 WO
9510326 Apr 1995 WO
9530373 Nov 1995 WO
9534259 Dec 1995 WO
9600042 Jan 1996 WO
9607360 Mar 1996 WO
9634568 Nov 1996 WO
9635469 Nov 1996 WO
9639914 Dec 1996 WO
9639962 Dec 1996 WO
9639964 Dec 1996 WO
9639965 Dec 1996 WO
9639967 Dec 1996 WO
9700646 Jan 1997 WO
9700647 Jan 1997 WO
9715238 May 1997 WO
9718765 May 1997 WO
9724073 Jul 1997 WO
9724074 Jul 1997 WO
9724992 Jul 1997 WO
9724993 Jul 1997 WO
9724994 Jul 1997 WO
9725101 Jul 1997 WO
9732551 Sep 1997 WO
9733523 Sep 1997 WO
9734540 Sep 1997 WO
9741786 Nov 1997 WO
9744071 Nov 1997 WO
9748345 Dec 1997 WO
9748346 Dec 1997 WO
9807468 Feb 1998 WO
9814131 Apr 1998 WO
9817185 Apr 1998 WO
9817186 Apr 1998 WO
9827877 Jul 1998 WO
9827879 Jul 1998 WO
9827880 Jul 1998 WO
9830144 Jul 1998 WO
9834550 Aug 1998 WO
9834558 Aug 1998 WO
9838925 Sep 1998 WO
9839038 Sep 1998 WO
9900060 Jan 1999 WO
9920185 Apr 1999 WO
9942037 Aug 1999 WO
9944506 Sep 1999 WO
9951155 Oct 1999 WO
9951158 Oct 1999 WO
0009053 Feb 2000 WO
0126570 Apr 2001 WO
0187154 May 2001 WO
0195819 Dec 2001 WO
0236028 May 2002 WO
02078557 Oct 2002 WO
03024339 Mar 2003 WO
2005125287 Dec 2005 WO
2008073727 Jun 2008 WO
2009094392 Jul 2009 WO
2011071482 Jun 2011 WO
Non-Patent Literature Citations (111)
Entry
EP Search Report for EP 03736488 3 pgs, Mailed Jun. 25, 2009.
PCT International Search Report for PCT/US96/18505, 3 pgs, Mailed Jan. 17, 1997.
PCT Notif of the Int'l Search Report and Written Opinion for PCT/US09/67001 6 pgs, Mailed Jan. 29, 2010.
Buchelt, et al. “Excimer Laser Ablation of Fibrocartilage: An In Vitro and In Vivo Study”, Lasers in Surgery and Medicine, vol. 11, pp. 271-279, 1991.
Costello et al., “Nd: YAG Laser Ablation of the Prostate as a Treatment for Benign Prostatic Hypertrophy”, Lasers in Surgery and Medicine, vol. 12, pp. 121-124, 1992.
Hardy et al., “Regional Myocardial Blood Flow and Cardiac mechanics in dog Hearts with CO2 laser-induced Intramyocardial Revascularization”, Basic Research in cardiology 85:179-196, 1990.
Mirhoseini et al., “New Concepts in Revascularization of the Myocardium”, Ann Thorac Surg 45:415-420, 1988.
Mirhoseini et al., “Revascularization of the heart by Laser”, J. of Microsurgery 2:253-260, 1981.
Mirhoseini et al., “Transmyocardial Laser Revascularization: A Review”, J. of Clinical Laser medicine & Surgery 11 (1):15-19, 1993.
Mirhoseini et al., “Transventricular Revascularization by Laser”, Lasers in Surgery and Medicine 2:187-198, 1982.
Rand et al., “Effect of Elecctrocautery on Fresh Human Articular Cartilage”, J. Arthro. Surg., vol. 1, pp. 242-246, 1985.
Walter et al., “Treatment of Acute Mycardial Infarction by Transmural Blood Supply from the Ventricular Cavity”, Erop. Surgery Res. 3:130-138, 1971.
Whittaker et al., “Transmural Channels Can Protect Ischemic Tissue”, Circulation 93(1):143-152, Jan. 1, 1996.
EP Search Report for EP01124768 2 pgs, Nov. 30, 2001.
EP Search Report for EP01935650 10 pgs, Mailed Jul. 26, 2006.
EP Search Report for EP01935650 8 pgs, Mailed May 3, 2005.
EP Search Report for EP02768969 3 pgs, Mailed Feb. 12, 2007.
EP Search Report for EP03762238 3 pgs, Mailed Jun. 2, 2006.
EP Search Report for EP94916716 2 pgs, Oct. 29, 1996.
EP Search Report for EP96941386 2 pgs, Nov. 27, 1998.
EP Search Report for EP98952032 2 pgs, Nov. 24, 2000.
PCT International Search Report for PCT/US00/07718 1pg, Mailed Sep. 5, 2000.
PCT International Search Report for PCT/US01/16006 1pg, Mailed Aug. 14, 2001.
PCT International Search Report for PCT/US02/31640 1pg, Mailed May 23, 2003.
PCT International Search Report for PCT/US03/04689 1 pg, Mailed Sep. 26, 2003.
PCT International Search Report for PCT/US03/12790 1 pg, Mailed Aug. 12, 2003.
PCT International Search Report for PCT/US03/20574 1 pg, Mailed May 25, 2005.
PCT International Search Report for PCT/US04/22803 1 pg, Mailed Apr. 29, 2005.
PCT International Search Report for PCT/US05/07038 1 pg, Mailed Sep. 2, 2005.
PCT International Search Report for PCT/US94/05168, 1 pg, Mailed Oct. 18, 1994.
PCT International Search Report for PCT/US98/20768 1pg, Mailed Jan. 20, 1999.
PCT International Search Report for PCT/US98/22327 1 pg, Mailed Feb. 9, 1999.
PCT IPER for PCT/US01/16006 3pgs, Apr. 16, 2002.
PCT IPER for PCT/US98/22327 4pgs, Aug. 27, 2000.
PCT Written Opinion for PCT/US04/22803 3pgs, Mailed Apr. 29, 2005.
PCT Written Opinion for PCT/US05/07038 3pgs, Mailed Sep. 2, 2005.
UK Search Report for GB0805061.9 1 pg, Jul. 15, 2008.
Barry et al., “The Effect of Radiofrequency-generated Thermal Energy on the Mechanical and Histologic Characteristics of the Arterial Wall in Vivo: Implications of Radiofrequency Angioplasty” American Heart Journal vol. 117, pp. 332-341, 1982.
Codman & Shurtleff, Inc. “The Malis Bipolar Coagulating and Bipolar Cutting System CMC-II” brochure, early, 2 pgs, 1991.
Codman & Shurtleff, Inc. “The Malis Bipolar Electrosurgical System CMC—III Instruction Manual” , 15 pgs, Jul. 1991.
Cook et al., “Therapeutic Medical Devices: Application and Design” , Prentice Hall, Inc., 3pgs, 1982.
Dennis et al. “Evolution of Electrofulguration in Control of Bleeding of Experimental Gastric Ulcers,” Digestive Diseases and Sciences, vol. 24, No. 11, 845-848, Nov. 1979.
Dobbie, A.K., “The Electrical Aspects of Surgical Diathermy, Bio Medical Engineering” Bio-Medical Engineering vol. 4, pp. 206-216, May 1969.
Elsasser, V.E. et al., “An Instrument for Transurethral Resection without Leakage of Current” Acta Medicotechnica vol. 24, No. 4, pp. 129-134, 1976.
Geddes, “Medical Device Accidents: With Illustrative Cases” CRC Press, 3 pgs, 1998.
Honig, W., “The Mechanism of Cutting in Electrosurgery” IEEE pp. 58-65, 1975.
Kramolowsky et al. “The Urological App of Electorsurgery” J. of Urology vol. 146, pp. 669-674, 1991.
Kramolowsky et al. “Use of 5F Bipolar Electrosurgical Probe in Endoscopic Urological Procedures” J. of Urology vol. 143, pp. 275-277, 1990.
Lee, B et al. “Thermal Compression and Molding of Artherosclerotic Vascular Tissue with Use” JACC vol. 13(5), pp. 1167-1171, 1989.
Letter from Department of Health to Jerry Malis dated Jan. 24, 1991, 3 pgs, Jan. 24, 1991.
Letter from Department of Health to Jerry Malis dated Jul. 25, 1985, 1 pg, Jul. 25, 1985.
Letter from Jerry Malis to FDA dated Jul. 25, 1985, 2 pgs, Jul. 25, 1985.
Lu, et al., “Electrical Thermal Angioplasty: Catheter Design Features, In Vitro Tissue Ablation Studies and In Vitro Experimental Findings,” Am J. Cardiol vol. 60, pp. 1117-1122, Nov. 1, 1987.
Malis, L., “Electrosurgery, Technical Note,” J. Neursurg., vol. 85, pp. 970-975, Nov. 1996.
Malis, L., “Excerpted from a seminar by Leonard I. Malis, M.D. at the 1995 American Association of Neurological Surgeons Meeting,” 1pg, 1995.
Malis, L., “Instrumentation for Microvascular Neurosurgery” Cerebrovascular Surgery, vol. 1, pp. 245-260, 1985.
Malis, L., “New Trends in Microsurgery and Applied Technology,” Advanced Technology in Neurosurgery, pp. 1-16, 1988.
Malis, L., “The Value of Irrigation During Bipolar Coagulation” See ARTC 21602, 1 pg, Apr. 9, 1993.
Nardella, P.C., SPIE 1068: pp. 42-49, Radio Frequency Energy and Impedance Feedback, 1989.
O'Malley, Schaum's Outline of Theory and Problems of Basic Circuit Analysis, McGraw-Hill, 2nd Ed., pp. 3-5, 1992.
Olsen MD, Bipolar Laparoscopic Cholecstectomy Lecture (marked confidential), 12 pgs, Oct. 7, 1991.
Pearce, John A. “Electrosurgery”, pp. 17, 69-75, 87, John Wiley & Sons, New York, 1986.
Pearce, John A., “Electrosurgery”, Handbook of Biomedical Engineering, chapter 3, Academic Press Inc., N.Y., pp. 98-113, 1988.
Piercey et al., “Electrosurgical Treatment of Experimental Bleeding Canine Gastric Ulcers” Gastroenterology vol. 74(3), pp. 527-534, 1978.
Protell et al., “Computer-Assisted Electrocoagulation: Bipolar v. Monopolar in the Treatment of Experimental Canine Gastric Ulcer Bleeding,” Gastroenterology vol. 80, No. 3, pp. 451-455, 1981.
Ramsey et al., “A Comparison of Bipolar and Monopolar Diathermy Probes in Experimental Animals”, Urological Research vol. 13, pp. 99-102, 1985.
Selikowitz et al., “Electric Current and Voltage Recordings on the Myocardium During Electrosurgical Procedures in Canines,” Surgery, Gynecology & Obstetrics, vol. 164, pp. 219-224, Mar. 1987.
Shuman, “Bipolar Versus Monopolar Electrosurgery: Clinical Applications,” Dentistry Today, vol. 20, No. 12, 7 pgs, Dec. 2001.
Slager et al. “Spark Erosion of Arteriosclerotic Plaques” Z. Kardiol. 76:Suppl. 6, pp. 67-71, 1987.
Slager et al. “Vaporization of Atherosclerotice Plaques by Spark Erosion” JACC 5(6): pp. 1382-1386, Jun. 1985.
Stoffels, E. et al., “Investigation on the Interaction Plasma-Bone Tissue”, E-MRS Spring Meeting, 1 pg, Jun. 18-21, 2002.
Stoffels, E. et al., “Biomedical Applications of Plasmas”, Tutorial presented prior to the 55th Gaseous Electronics Conference in Minneapolis, MN, 41 pgs, Oct. 14, 2002.
Stoffels, E. et al., “Plasma Interactions with Living Cells”, Eindhoven University of Technology, 1 pg, 2002.
Stoffels, E. et al., “Superficial Treatment of Mammalian Cells using Plasma Needle”, J. Phys. D: Appl. Phys. 26, pp. 2908-2913, Nov. 19, 2003.
Stoffels, E. et al., “Plasma Needle”, Eindhoven University of Technology, 1 pg, Nov. 28, 2003.
Stoffels, E. et al., “Plasma Physicists Move into Medicine”, Physicsweb, 1 pg, Nov. 2003.
Stoffels, E. et al., “Plasma Treated Tissue Engineered Skin to Study Skin Damage”, Biomechanics and Tissue Engineering, Materials Technology, 1 pg, 2003.
Stoffels, E. et al., “Plasma Treatment of Dental Cavities: A Feasibility Study”, IEEE Transaction on Plasma Science, vol. 32, No. 4, pp. 1540-1542, Aug. 2004.
Stoffels, E. et al., “The Effects of UV Irradiation and Gas Plasma Treatment on Living Mammalian Cells and Bacteria: A Comparative Approach”, IEEE Transaction on Plasma Science, vol. 32, No. 4, pp. 1544-1550, Aug. 2004.
Stoffels, E. et al., “Electrical and Optical Characterization of the Plasma Needle”, New Journal of Physics 6, pp. 1-14, Oct. 28, 2004.
Stoffels, E. et al., “Where Plasma Meets Plasma”, Eindhoven University of Technology, 23 pgs, 2004.
Stoffels, E. et al., “Gas Plasma effects on Living Cells”, Physica Scripta, T107, pp. 79-82, 2004.
Stoffels, E. et al., “Plasma Treatment of Mammalian Vascular Cells: A Quantitative Description”, IEEE Transaction on Plasma Science, vol. 33, No. 2, pp. 771-775, Apr. 2005.
Stoffels, E. et al., “Deactivation of Escherichia coli by the Plasma Needle”, J. Phys. D: Appl. Phys. 38, pp. 1716-1721, May 20, 2005.
Stoffels, E. et al., “Development of a Gas Plasma Catheter for Gas Plasma Surgery”, XXVIIth ICPIG, Endoven University of Technology, pp. 18-22, Jul. 2005.
Stoffels, E. et al., “Development of a Smart Positioning Sensor for the Plasma Needle”, Plasma Sources Sci. Technol. 15, pp. 582-589, Jun. 27, 2006.
Stoffels, E. et al., Killing of S. mutans Bacteria Using a Plasma Needle at Atmospheric Pressure, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1317-1324, Aug. 2006.
Stoffels, E. et al., “Plasma-Needle Treatment of Substrates with Respect to Wettability and Growth of Excherichia coli and Streptococcus mutans”, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1325-1330, Aug. 2006.
Stoffels, E. et al., “Reattachment and Apoptosis after Plasma-Needle Treatment of Cultured Cells”, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1331-1336, Aug. 2006.
Stoffels, E. et al., “UV Excimer Lamp Irradiation of Fibroblasts: The Influence on Antioxidant Homostasis”, IEEE Transaction on Plasma Science, vol. 34, No. 4, pp. 1359-1364, Aug. 2006.
Stoffels, E. et al., “Plasma Needle for In Vivo Medical Treatment: Recent Developments and Perspectives”, Plasma Sources Sci. Technol. 15, pp. S169-S180, Oct. 6, 2006.
Swain, C.P., et al., “Which Electrode, a Comparison of four endoscopic methods of electrocoagulation in experimental bleeding ulcers” Gut vol. 25, pp. 1424-1431, 1987.
Tucker, R. et al. “A Comparison of Urologic Application of Bipolar Versus Monopolar Five French Electrosurgical Probes” J. of Urology vol. 141, pp. 662-665, 1989.
Tucker, R. et al. “In vivo effect of 5 French Bipolar and Monopolar Electrosurgical Probes on the Porcine Bladder ” Urological Research vol. 18, pp. 291-294, 1990.
Tucker, R. et al., “Demodulated Low Frequency Currents from Electrosurgical Procedures,” Surgery, Gynecology and Obstetrics, 159:39-43, 1984.
Tucker, R. et al., Abstract P14-11, p. 248, “A Bipolar Electrosurgical Turp Loop”, Nov. 1989.
Valley Forge Scientific Corp., “Summary of Safety and Effective Information from 510K”, 2pgs, 1991.
Valley Forge's New Products, CLINICA, 475, 5, Nov. 6, 1991.
Valleylab SSE2L Instruction Manual, 11 pgs, Jan. 6, 1983.
Valleylab, Inc. “Valleylab Part No. 945 100 102 A” Surgistat Service Manual, pp. 1-46, Jul. 1988.
Wattiez, Arnaud et al., “Electrosurgery in Operative Endoscopy,” Electrosurgical Effects, Blackwell Science, pp. 85-93, 1995.
Wyeth, “Electrosurgical Unit” pp. 1181-1202, 2000.
BiLAP IFU 910033-002 Rev A for BiLAP Model 3527, L-Hook; BiLAP Model 35:25, J-Hook; BiLAP Model 3529, High Angle, 2 pgs, Nov. 30, 1993.
BiLAP IFU 910026-001 Rev A for BiLAP Model 3525, J-Hook, 4 pgs, May 20, 1991.
BiLAP Generator Settings, Jun. 1991.
Tucker et al. “The interaction between electrosurgical generators, endroscopic electrodes, and tissue,” Gastrointestinal Endoscopy, vol. 38, No. 2, pp. 118-122, 1992.
EP Search Report for EP 07118068 3pgs, Mailed Dec. 27, 2010.
EP Search Report for EP 04778347 4pgs, Feb. 22, 2011.
UK Search Report for GB0921635.9 3pgs, Apr. 12, 2010.
UK Search Report for GB1106425.0 6 pages, Mailed Aug. 16, 2011.
UK combined Search and Examination Report for GB1121048.1 3pgs, Apr. 18, 2012.
Related Publications (1)
Number Date Country
20100042095 A1 Feb 2010 US